| |  Modern anticancer medications that combine tumor-fighting drugs with proteins that specifically target cancer cells are a relatively new class of drug, often given to patients for whom standard chemotherapy has not worked. | |
|
| |  Researchers at The University of Texas MD Anderson Cancer Center have discovered a new way in which T cells attack acute myeloid leukemia (AML) cells, which may help explain why AML is particularly sensitive to immune-based treatments and could guide the development of future cancer immunotherapies. | |
|
| |  In a double-blind pilot trial, lactoferrin-enriched yogurt added to routine iron supplementation helped prevent ferritin decline in pregnant women with gestational diabetes and reduced iron stores. The intervention was well tolerated and produced modest changes in selected gut bacteria, but did not significantly improve anemia or metabolic outcomes. | |
|
| |  A major national cooperative group clinical trial led by Mayo Clinic researchers found that continuing maintenance therapy with lenalidomide beyond two years after initial treatment for standard-risk multiple myeloma did not improve overall survival compared with stopping treatment after two years. | |
|
| |  Irritable patient behavior influences physician emotions but does not alter clinical assessments, emphasizing the need for emotional resilience training. | |
|
| |  Siemens Healthineers now offers U.S. laboratories a comprehensive hematology solution that brings together automation, middleware, and remote digital slide review to help deliver time-sensitive patient results with greater consistency. | |
|
| |  In a phase 2 trial of patients with gastrointestinal cancers, avatrombopag helped 70% of those receiving chemotherapy to stay on treatment schedule, compared with 17% receiving placebo. | |
|
| |  Researchers at The University of Texas MD Anderson Cancer Center were able to eradicate measurable residual disease (MRD) in B-cell acute lymphoblastic leukemia (ALL) patients, a critical step in improving long-term survival outcomes, by treating with the antibody-drug conjugate (ADC) inotuzumab ozogamicin. | |
|
| |  BET proteins, especially BRD4, drive oncogenic transcription in solid tumours. First‑generation inhibitors (JQ1, molibresib, birabresib) showed preclinical promise but failed clinically due to modest efficacy, dose‑limiting thrombocytopenia, and resistance (isoform switching, compensatory PI3K/AKT/WNT signalling). | |
|
| |  Nearly 90 years after Ugo Cerletti and Lucio Bini introduced electroconvulsive therapy (ECT), brain stimulation therapies such as ECT and Repetitive Transcranial Magnetic Stimulation (rTMS) are common in psychiatry because they are highly effective for treating depression and schizophrenia, yet their cellular mechanisms remain poorly understood | |
|
| |  Bio-Techne Corporation, a global provider of life science tools, reagents, and diagnostic products, today announced the launch of new additions to its R&D Systems™ AI-Engineered Designer Protein portfolio, designed to improve reproducibility and performance across advanced cell culture and cell therapy development workflows. | |
|
| |  Researchers at The University of Texas MD Anderson Cancer Center have discovered that an investigational epigenetic therapy remained effective in treatment-resistant acute myeloid leukemia (AML) through activating the Hippo pathway, a tumor-suppressing pathway linked to cancer growth and drug resistance. | |
